Bliss GVS Pharma Ltd

Resolutions

• Ordinary Resolution: Appointment of Santosh Parab as Non-Executive Non-Independent Director.
• E-voting window: August 21, 2026 to September 19, 2026.
• Cut-off date for eligibility: August 14, 2026.
• Outcome: Pending; results to be announced by Sep 22, 2026.
• Scrutinizer appointed: Vijay Yadav.
• Profile: Santosh Parab, CA; DIN 01622988; 35+ years in audit.
• Term: liable to retire by rotation; appointment as Additional Director w.e.f. July 3, 2026.
• Impact: governance shift with one additional director; no capital actions.

ESOP grant details

• Grant of 320,000 stock options under Bliss GVS Pharma ESOP 2019 approved by Nomination and Remuneration Committee.
• Total options cover 320,000 equity shares of Re 1 each; options convert to equal shares.
• Exercise price Rs 43 per option, determined using last closing price minus 91.32% discount.
• Vesting in four equal instalments: 12, 24, 36, and 48 months from grant.
• Minimum one-year gap between grant and vesting; exercise period max six months post-vesting.
• Lock-in: equity shares arising from vested options are locked in for six months from allotment.
• Scheme is compliant with SEBI SBEB regulations 2014/2021.

Financial results approved

• Unaudited standalone and consolidated results for quarter ended June 30, 2026 approved.
• Audit Committee reviewed results; limited review reports submitted.

Director appointment

• Draft Postal Ballot Notice for Santosh Parab as Non-Executive Non-Independent Director.

Regulatory/compliance and auditor remarks

• Board approvals under SEBI LODR Regulations 30 and 33.
• Statutory auditors issued limited review reports with unmodified conclusions.

Summary

• Target company is Bliss GVS Pharma Ltd.
• Disclosing party: Life Insurance Corporation of India Central Office; not promoter group.
• Transaction Type: Disposal of shares by LIC through market sale.
• Pre-transaction holding: 5,276,355 shares, 5.110%.
• Disposal details: 2,132,071 shares (2.151%), market sale.
• Post-transaction holding: 3,144,284 shares, 2.959%.
• Date(s) of transaction: 09.09.2020–10.08.2026.
• Share capital context: before/after equity capital 10,62,43,972.00; unchanged.
• Total diluted share/voting capital after: NA.

Meeting Details

• Board meeting on August 12, 2026 at the registered office; time not disclosed.

Key Agenda Items

• Agenda includes approval of unaudited standalone and consolidated results for quarter ended June 30, 2026.

Other Notes

• Trading window closed for designated persons from July 01, 2026 until 48 hours after unaudited results announcement.

Open offer details

• Open offer to acquire up to 2,77,26,848 Bliss GVS Pharma equity shares, 26% of expanded voting share capital.
• Acquirer Anupam Rasayan India Limited and PAC act in concert under SEBI SAST Regulations.
• Pre-offer advertisement published July 27, 2026; Detailed Public Statement dated May 30, 2026.
• Regulatory compliance with SEBI SAST Regulations 2011 amended.

IEPF transfer notice

• Notice to transfer unpaid or unclaimed dividends to IEPF under Companies Act and Rules.
• Shareholder communication sent July 25, 2026; details uploaded on the company website.
• Unclaimed dividends/shares liable to transfer to IEPF unless claimed by September 15, 2026.
• For physical shares, duplicate certificates will be issued solely for transfer; originals cancelled.
• Claim process via e-Form IEPF-5 with prescribed documents.
• Deadline September 15, 2026, or as extended; no further company action required.